Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – What’s Next?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped up before the market opened on Thursday . The stock had previously closed at $42.11, but opened at $46.95. Zealand Pharma A/S shares last traded at $46.95, with a volume of 100 shares trading hands.

Analysts Set New Price Targets

ZLDPF has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, Wolfe Research downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Three analysts have rated the stock with a Strong Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, Zealand Pharma A/S currently has an average rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

The company has a market cap of $3.36 billion, a PE ratio of 3.48 and a beta of 0.88. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $47.30 and its two-hundred day moving average is $54.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. On average, equities research analysts anticipate that Zealand Pharma A/S will post 2.37 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.